Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Blood (2024) 144 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2024-207033

Published: 2024

Journal Articles

Inhibition of NOTCH4 Sensitizes FLT3/ITD Acute Myeloid Leukemia Cells to FLT3 Tyrosine Kinase Inhibition

Ruiqi Zhu, Courtney Shirley, Haihua Chu, Li Li, Bao Nguyen, Jaesung Seo, Tessa Seale, Amy Duffield, Louis M. Staudt, Mark J. Levis, Yu Hu, Donald Small

Blood (2023) 142 (Supplement 1): 5769.

https://doi.org/10.1182/blood-2023-190696

Published: 2023

Journal Articles

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Sung-Soo Yoon, Dongyeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yoo Jin Lee, Joseph Clarey, Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2023) 142 (Supplement 1): 4283.

https://doi.org/10.1182/blood-2023-185606

Published: 2023

Journal Articles

SHP2 Inhibition Overcomes Adaptive and Acquired Resistance to FLT3 TKI to Improve Efficacy Against FLT3/ITD AML

Tessa Seale, Li Li, J. Kyle Bruner, Bao Nguyen, Mark J. Levis, Christine Pratilas, Donald Small

Blood (2023) 142 (Supplement 1): 2790.

https://doi.org/10.1182/blood-2023-184338

Published: 2023

Journal Articles

Evaluation of Synergistic Anti-Leukemic Efficacy of PHI-101 in Preclinical Model of FLT3-ITD Acute Myeloid Leukemia

Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Li Li, Bao Nguyen, Tessa Seale, Donald Small

Blood (2023) 142 (Supplement 1): 5949.

https://doi.org/10.1182/blood-2023-185759

Published: 2023

Journal Articles

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Joseph Clarey, Jeejin Im, Suntae Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, Jeong Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2022) 140 (Supplement 1): 3365–3366.

https://doi.org/10.1182/blood-2022-165000

Published: 2022

Journal Articles

A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Anish Puliyayil, Joseph Clarey, Jeejin Im, Ky-Youb Nam, Kyu-Tae Kim, June H-J. Han, Jeong-Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2021) 138 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2021-149395

Published: 2021

Journal Articles

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Ky-Youb Nam, PhD, Jeejin Im, June H-J H-J Han, Kyu-Tae Kim, PhD, Jeong-Hyeok Yoon, PhD, Hanna Cho, PhD, Seung-Hye Choi, PhD, David Young, MD, Bao Nguyen, Ruiqi Zhu, PhD, Li Li, MD,PhD, Donald Small, MD, PhD, Taebo Sim, PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139044

Published: 2020

Journal Articles

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Ruiqi Zhu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Amy S. Duffield, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 2564.

https://doi.org/10.1182/blood-2019-131635

Published: 2019

Journal Articles

DOCK2 Knockdown Mitigates Disease Progression in Murine Models Harboring a FLT3/ITD Mutation

Min Wu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2017) 130 (Supplement 1): 1216.

https://doi.org/10.1182/blood.V130.Suppl_1.1216.1216

Published: 2017

Journal Articles

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

Lauren Y. Lee, Daniela Hernandez, Trivikram Rajkhowa, Samuel C. Smith, Jayant Ranganathan Raman, Bao Nguyen, Donald Small, Mark Levis

Blood (2017) 129 (2): 257–260.

https://doi.org/10.1182/blood-2016-10-745133

Published: 2017

Includes: Supplemental data

Journal Articles

Arsenic Trioxide Synergizes with FLT3 Tyrosine Kinase Inhibitors to Kill FLT3-ITD + Leukemic Cells through Depressed Production and Degradation of FLT3 Protein

Kozo Nagai, MD PhD, Lihong Hou, MD PhD, Li Li, MD PhD, Bao Nguyen, M.S., Courtney M Shirley, PhD, Hayley S Ma, PhD, Mark J. Levis, MD PhD, Amy S. Duffield, MD PhD, Donald Small, MD PhD

Blood (2016) 128 (22): 1568.

https://doi.org/10.1182/blood.V128.22.1568.1568

Published: 2016

Journal Articles

All- trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD + leukemia stem cells in vitro and in vivo

Hayley S. Ma, Sarah M. Greenblatt, Courtney M. Shirley, Amy S. Duffield, J. Kyle Bruner, Li Li, Bao Nguyen, Eric Jung, Peter D. Aplan, Gabriel Ghiaur, Richard J. Jones, Donald Small

Blood (2016) 127 (23): 2867–2878.

https://doi.org/10.1182/blood-2015-05-646786

Published: 2016

Includes: Supplemental data

Journal Articles

FLT3 Inhibition and Retinoid Signaling Overcome Stromal Protection to Target FLT3/ITD-Expressing Leukemia Stem Cells in the Bone Marrow Microenvironment

Hayley S Ma, PhD, Megan E McCray, BA, Courtney M Shirley, PhD, Amy S. Duffield, MD PhD, J Kyle Bruner, Li Li, PhD, Bao Nguyen, M.S., Sarah Greenblatt, PhD, Eric Jung, BS, Peter D. Aplan, MD, Richard J Jones, MD, Donald Small, MD PhD, Gabriel Ghiaur, MD PhD

Blood (2015) 126 (23): 790.

https://doi.org/10.1182/blood.V126.23.790.790

Published: 2015

Journal Articles

Dnmt3a Deletion Cooperates with the Flt3-ITD Mutation to Drive Leukemogenesis in a Murine Model

Jennifer L Poitras, BS, Diane Heiser, PhD, Li Li, PhD, Bao Nguyen, M.S., Amy S. Duffield, MD PhD, Christopher Gamper, MD PhD, Donald Small, MD PhD

Blood (2014) 124 (21): 3568.

https://doi.org/10.1182/blood.V124.21.3568.3568

Published: 2014

Journal Articles

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo

Hayley Ma, Bao Nguyen, Li Li, Sarah Greenblatt, Allen Williams, Ming Zhao, Mark Levis, Michelle Rudek, Amy Duffield, Donald Small

Blood (2014) 123 (10): 1525–1534.

https://doi.org/10.1182/blood-2013-08-523035

Published: 2014

Includes: Supplemental data

Journal Articles

TTT-3002 Is Active Against Relapsed/Refractory AML Patient Bone Marrow With FLT3 TKI-Resistance Mutations At Residue D835

Hayley S Ma, Ph.D., Bao Nguyen, M.S., Mark Levis, MD, PhD, Allen B Williams, PhD, Donald Small, MD, PhD

Blood (2013) 122 (21): 3818.

https://doi.org/10.1182/blood.V122.21.3818.3818

Published: 2013

Journal Articles

TTT-3002 Is a Novel FLT3 Tyrosine Kinase Inhibitor That Has the Potential to Overcome Some of the Limitations of Current FLT3 Inhibitors in Treatment of Acute Myeloid Leukemia

Hayley S Wall, B.S., Bao Nguyen, M.S., Li Li, PhD, Sarah M Greenblatt, PhD, Patrick Brown, MD, Mark J. Levis, MD, PhD, Donald Small, MD, PhD

Blood (2012) 120 (21): 866.

https://doi.org/10.1182/blood.V120.21.866.866

Published: 2012

Journal Articles

Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia

Allen B. Williams, Li Li, Bao Nguyen, Patrick Brown, Mark Levis, Donald Small

Blood (2012) 120 (15): 3069–3079.

https://doi.org/10.1182/blood-2012-01-403493

Published: 2012

Journal Articles

Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model

Sarah Greenblatt, Li Li, Christopher Slape, Bao Nguyen, Rachel Novak, Amy Duffield, David Huso, Stephen Desiderio, Michael J. Borowitz, Peter Aplan, Donald Small

Blood (2012) 119 (12): 2883–2894.

https://doi.org/10.1182/blood-2011-10-382283

Published: 2012

Includes: Supplemental data

NARROW

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Inhibition of NOTCH4 Sensitizes FLT3/ITD Acute Myeloid Leukemia Cells to FLT3 Tyrosine Kinase Inhibition

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

SHP2 Inhibition Overcomes Adaptive and Acquired Resistance to FLT3 TKI to Improve Efficacy Against FLT3/ITD AML

Evaluation of Synergistic Anti-Leukemic Efficacy of PHI-101 in Preclinical Model of FLT3-ITD Acute Myeloid Leukemia

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

DOCK2 Knockdown Mitigates Disease Progression in Murine Models Harboring a FLT3/ITD Mutation

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

Arsenic Trioxide Synergizes with FLT3 Tyrosine Kinase Inhibitors to Kill FLT3-ITD + Leukemic Cells through Depressed Production and Degradation of FLT3 Protein

All- trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD + leukemia stem cells in vitro and in vivo

FLT3 Inhibition and Retinoid Signaling Overcome Stromal Protection to Target FLT3/ITD-Expressing Leukemia Stem Cells in the Bone Marrow Microenvironment

Dnmt3a Deletion Cooperates with the Flt3-ITD Mutation to Drive Leukemogenesis in a Murine Model

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo

TTT-3002 Is Active Against Relapsed/Refractory AML Patient Bone Marrow With FLT3 TKI-Resistance Mutations At Residue D835

TTT-3002 Is a Novel FLT3 Tyrosine Kinase Inhibitor That Has the Potential to Overcome Some of the Limitations of Current FLT3 Inhibitors in Treatment of Acute Myeloid Leukemia

Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia

Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only